No profile data available.
Bristol-Myers Squibb Company (BMY) is a healthcare company in the additional cancer treatment drugs industry, based in Princeton, United States, with about 32,500 full-time employees.
It reported revenue of $48.20 billion for fiscal year 2025, down 0.2% from fiscal year 2024, and net income of $7.05 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $12.97 billion, up 5.7% from a year before. United States was its largest region in fiscal year 2025, with 71% of revenue. Its market capitalization was $120.77 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Bristol-Myers Squibb reported $48.20 billion in revenue for fiscal year 2025, down 0.2% from $48.30 billion in fiscal year 2024. In Q2 2026 revenue was $12.97 billion.
United States: 71% of revenue by region in fiscal year 2025, followed by International (29%).
$120.77 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Merck & Co., Inc. (MRK), Revolution Medicines, Inc. (RVMD), Exelixis, Inc. (EXEL), Summit Therapeutics Inc. (SMMT).